Ra Pharmaceuticals, Inc.
DelistedCIK 1481512fmd_0Z5F1KJ73TJ4PX82JS30SMTTJBManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2014 to Dec 31, 2019, 21 periods
| Line item | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 |
|---|---|---|---|---|---|---|
| Total revenues | 5 | 4 | 5 | – | 3 | 3 |
| Research and development | 10 | 15 | 28 | 45 | 54 | 83 |
| Total operating expenses | 12 | 17 | 33 | 55 | 69 | 110 |
| Operating income | (7) | (13) | (28) | (55) | (66) | (107) |
| Other non-operating income (expense) | 2 | (1) | (1) | 1 | 1 | 4 |
| Income before taxes | (6) | (14) | (29) | (54) | (65) | (103) |
| Income tax expense | (0) | (0) | (0) | (0) | (0) | – |
| Net income from continuing operations | (5) | (14) | (29) | (54) | (65) | – |
| Net income | (5) | (14) | (29) | (54) | (65) | (103) |
| Net income to common shareholders | (5) | (12) | (29) | (54) | – | – |